Watch Demo

Galmed Pharmaceuticals Ltd (GLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Galmed Pharmaceuticals Ltd (GLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
  • Publish Date:November 2018

  • Number of Pages:38

  • Report ID:5567550

  • Format:PDF

  • Publisher:GlobalData

$ 250

Summary

Summary
Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company.The company focuses on the development of therapeutics for the treatment of liver diseases.

It develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd (GLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.

The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
- Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company’s operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of contents

Table of Contents 3
List of Tables 4
List of Figures 4
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11
Partnerships 12
Galmed Pharma Enters into Agreement with University of California 12
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13
Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14
Licensing Agreements 15
Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15
Equity Offering 16
Galmed Pharma Prices Public Offering of Shares for USD75 Million 16
Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18
Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19
Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20
Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21
Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22
One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23
Galmed Pharma Completes IPO For US$44 Million 24
Galmed Pharmaceuticals Ltd - Key Competitors 26
Galmed Pharmaceuticals Ltd - Key Employees 27
Galmed Pharmaceuticals Ltd - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 05, 2018: Galmed Pharmaceuticals provides business update and reports third quarter 2018 financial results 29
May 09, 2018: Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results 30
Nov 09, 2017: Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 31
Jul 31, 2017: Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 32
May 15, 2017: Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results 33
Mar 23, 2017: Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 34
Corporate Communications 36
Jun 08, 2017: Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors 36
Legal and Regulatory 37
Feb 07, 2018: Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11
Galmed Pharma Enters into Agreement with University of California 12
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13
Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14
Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15
Galmed Pharma Prices Public Offering of Shares for USD75 Million 16
Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18
Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19
Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20
Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21
Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22
One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23
Galmed Pharma Completes IPO For US$44 Million 24
Galmed Pharmaceuticals Ltd, Key Competitors 26
Galmed Pharmaceuticals Ltd, Key Employees 27
Galmed Pharmaceuticals Ltd, Subsidiaries 28

List of Figures
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.